Pain Management

The FDA has approved Belbuca buccal film for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

The Centers for Disease Control and Prevention released final guidelines today that provide recommendations for prescribers with a goal of improved care and safety of patients being treated for chronic pain.

The risks of undertreating pain in the pediatric population are significant.

The FDA has accepted Egalet Corporation's new drug application for morphine sulfate extended-release tablets (Arymo ER).

To better understand the risks of Essure, a permanent method of birth control, the FDA has called for a new mandatory clinical study to look at its risks.

Iroko Pharmaceuticals' meloxicam (Vivlodex) capsules, designed to treat osteoarthritis pain, are now available by prescription at pharmacies across the United States.

A Super Bowl 50 commercial may be encouraging patients to seek help for their constipation.

Although clinicians are able to identify the causes of neuropathic pain, the mechanism behind its treatment is more difficult to distinguish.

The American College of Medical Toxicology recently issued position statements on opioid prescribing.

More than 100 million Americans experience pain each day, and it has been associated with a $500 billion economic burden in the United States.

Whether transient, spontaneous, or a triggered exacerbation of adequately controlled baseline aches, breakthrough pain is a difficult symptom for providers to gauge.

Data from large survey reports suggest that more than 80% of Americans who undergo surgery experience some level of postsurgical pain.

Overdose deaths involving opioids are on the rise in the United States.

Because patients are getting varicella vaccines, it is necessary for them to receive the zoster vaccine once they reach the appropriate age.

Neuropathic pain is one of the most difficult syndromes to treat.

Retrospective drug utilization review programs can reduce potentially unsafe concomitant opioid and central nervous system (CNS) medication use.

Black children with severe pain are less likely to receive opioids in emergency departments than white children, a recent study suggests.

The placebo effect is growing stronger in US clinical trials for chronic pain medications, according to a recent study.

Citing a rare, yet serious risk of slowed breathing, the FDA is evaluating the use of the opioid pain medication tramadol in the pediatric population.

Touted as a way to reduce pain, speed injury recovery, and improve mood, cryotherapy involves exposing the body to temperatures up to minus 300 degrees Fahrenheit.

Patients take acetaminophen and ibuprofen for minor pain and fever, but are they interchangeable?

Many sleepwalkers who injure themselves during their sleep do not experience pain until the next morning, which may lead them to the pharmacy for OTC pain relief.

The FDA has accepted Espero Pharmaceuticals' new drug application for GoNitro, a product designed to treat an attack or prophylaxis of angina pectoris due to coronary artery disease.

Treating low back pain with physical therapy soon after symptoms start does not make a clinically important difference when compared with starting therapy later.

The FDA has approved Endo Pharmaceuticals and BioDelivery Sciences' buprenorphine buccal film (Belbuca) for the management of chronic pain.